Seven Fleet Capital Management LP Invests $510,240 in BioCryst Pharmaceuticals, Inc. $BCRX

Seven Fleet Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 51,024 shares of the biotechnology company’s stock, valued at approximately $510,240.

A number of other hedge funds and other institutional investors have also modified their holdings of BCRX. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares during the last quarter. Allworth Financial LP bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $52,000. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth about $77,000. Envestnet Portfolio Solutions Inc. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

BCRX has been the subject of several recent analyst reports. Royal Bank Of Canada cut their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wedbush decreased their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Price Performance

BCRX traded down $0.05 during midday trading on Friday, reaching $9.82. 2,702,936 shares of the company’s stock were exchanged, compared to its average volume of 4,815,490. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22. The business’s 50-day moving average price is $9.70 and its 200 day moving average price is $9.05. The stock has a market capitalization of $2.51 billion, a PE ratio of -6.55 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. During the same quarter in the previous year, the company posted $0.15 earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 33.6% compared to the same quarter last year. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.